Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's Disease

Fecha de inicio: 1 de julio de 2004

INCLUSION CRITERIA: Patient is between the ages of 40 and 90 (inclusive). Patient will have a diagnosis of AD; the study will be confined to patients who are able to provide consent (pass a capacity assessment). The modified Hachinski Ischemia Score must be less than 4. Brain MRI performed within 15 months of enrollment must be compatible with the diagnosis of AD. Patient and/or caregiver are willing to adhere to protocol requirements as evidenced by written, informed consent. EXCLUSION CRITERIA: Patients meeting any of the following exclusion criteria during screening or during the study will not be enrolled or will be immediately excluded from the study, as appropriate: Patient has a history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk. Patient has clinically significant laboratory abnormalities that would preclude administration of lithium and divalproex. Patient is taking a prohibited concomitant medication. The following medications are forbidden for at least one month prior to the treatment phase (unless otherwise noted) and during the course of the study: Any investigational drugs; Anti-depressants (eligibility will be considered as long as dosage remains stable throughout the study); Anticonvulsants and other mood stabilizing drugs; Treatment that may provoke lithium toxicity due to reduced renal clearance, including metronidazole, spectinomycin, tetracycline; Treatment that may substantially increase steady-state plasma lithium levels resulting in lithium toxicity, including angiotensin-converting enzyme inhibitors, NSAIDS, diuretics; Treatment that may increase the risk of neurotoxicity, including calcium channel blocking agents; Drugs that may increase urinary lithium excretion resulting in lower serum lithium concentrations, such as acetazolamide, urea, xanthine preparations, alkalinizing agents such as sodium bicarbonate, theophylline; Drugs that interact with lithium, including methyldopa; Neuroleptics (eligibility will be considered as long as dosage remains stable throughout the study). If patient is on existing atypical neuroleptic drugs, these will be continued at the same dose. Patients will not start a new prescription for atypical antipsychotics during the study; Drugs that may prolong the effects of lithium, including neuromuscular blocking agents; Digoxin, warfarin. Patient has not been using an adequate contraceptive method for the last 30 days or unwilling to continue contraception throughout the study, or is not at least one year post-menopausal (if female). Patient is pregnant or breastfeeding. Patient has participated in a clinical study with an investigational drug within the last 30 days. Patient has a condition (such as active drug or alcohol abuse) that, in the opinion of the investigators, would interfere with compliance or safety. Patient has known hypersensitivity to lithium or divalproex. Patient's inability to swallow tablets or to comply with medication schedule. Patient has no adequate caregiver. Patient and/or caregiver are unwilling to sign an informed consent or to comply with protocol requirements. Patient is unwilling to have lumbar puncture.